PMID- 31796983
OWN - NLM
STAT- MEDLINE
DCOM- 20200925
LR  - 20200925
IS  - 1433-9285 (Electronic)
IS  - 0933-7954 (Linking)
VI  - 55
IP  - 5
DP  - 2020 May
TI  - Cannabis use in individuals at clinical high-risk for psychosis: a comprehensive 
      review.
PG  - 527-537
LID - 10.1007/s00127-019-01810-x [doi]
AB  - PURPOSE: The objectives of this review were to understand the prevalence of 
      cannabis use and how cannabis is associated with transition to psychosis, 
      symptoms, cognition, trauma and family history in clinical high risk (CHR) for 
      psychosis individuals. METHOD: A systematic literature review was conducted to 
      find studies that examined cannabis use in CHR individuals, with no limitations 
      on the geographical area, and included publications up to November 2018. Studies 
      were screened for inclusion based on detailed criteria, and data were extracted 
      on cannabis use and associated outcomes. A quantitative synthesis by 
      meta-analysis was performed where appropriate, otherwise, a qualitative synthesis 
      was conducted. RESULTS: Overall, 36 studies met inclusion criteria with an 
      average age of 20.1 years and 58.4% males. Prevalence of lifetime cannabis use 
      was 48.7%, whereas current cannabis use was 25.8% and the prevalence of cannabis 
      use disorder/abuse or dependence was 14.9% across the studies. All cannabis use 
      results had statistically significant heterogeneity ranging from 75.7 to 92.8%. 
      The most commonly reported association with cannabis use was transition to 
      psychosis, although the pooled relative risk (RR) was not statistically 
      significant (RR = 1.11, 95% confidence interval = 0.89-1.37). For all other 
      outcomes including symptoms, cognition, trauma, and family history, the evidence 
      was limited, and therefore, the results were synthesized qualitatively. 
      CONCLUSION: Almost half of CHR individuals have ever used cannabis. However, 
      cannabis use has not been thoroughly researched regarding frequency and dose of 
      use, and how other factors, such as symptoms, are associated with cannabis in CHR 
      individuals.
FAU - Farris, Megan S
AU  - Farris MS
AUID- ORCID: 0000-0003-0640-9512
AD  - Hotchkiss Brain Institute, Department of Psychiatry, Mathison Centre for Mental 
      Health Research and Education, University of Calgary, 3280 Hospital Drive NW, 
      Calgary, AB, T2N 4Z6, Canada.
FAU - Shakeel, Mohammed K
AU  - Shakeel MK
AD  - Hotchkiss Brain Institute, Department of Psychiatry, Mathison Centre for Mental 
      Health Research and Education, University of Calgary, 3280 Hospital Drive NW, 
      Calgary, AB, T2N 4Z6, Canada.
FAU - Addington, Jean
AU  - Addington J
AD  - Hotchkiss Brain Institute, Department of Psychiatry, Mathison Centre for Mental 
      Health Research and Education, University of Calgary, 3280 Hospital Drive NW, 
      Calgary, AB, T2N 4Z6, Canada. jmadding@ucalgary.ca.
LA  - eng
GR  - RO1MH105178/NH/NIH HHS/United States
GR  - RO1MH105178/NH/NIH HHS/United States
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20191203
PL  - Germany
TA  - Soc Psychiatry Psychiatr Epidemiol
JT  - Social psychiatry and psychiatric epidemiology
JID - 8804358
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Female
MH  - Humans
MH  - Male
MH  - Marijuana Abuse/complications/*epidemiology
MH  - Prevalence
MH  - *Psychotic Disorders
MH  - Risk
MH  - Young Adult
OTO - NOTNLM
OT  - Cannabis
OT  - Clinical high risk
OT  - Meta-analysis
OT  - Psychosis
OT  - Systematic review
EDAT- 2019/12/05 06:00
MHDA- 2020/09/26 06:00
CRDT- 2019/12/05 06:00
PHST- 2019/09/13 00:00 [received]
PHST- 2019/11/28 00:00 [accepted]
PHST- 2019/12/05 06:00 [pubmed]
PHST- 2020/09/26 06:00 [medline]
PHST- 2019/12/05 06:00 [entrez]
AID - 10.1007/s00127-019-01810-x [pii]
AID - 10.1007/s00127-019-01810-x [doi]
PST - ppublish
SO  - Soc Psychiatry Psychiatr Epidemiol. 2020 May;55(5):527-537. doi: 
      10.1007/s00127-019-01810-x. Epub 2019 Dec 3.